Poor drug distribution as a possible explanation for the results of the PRECISE trial

Journal of Neurosurgery

Volumn 113, Issue 2, 2010, Pages 301-309

  Sampson, John H ^a,c,ah   Archer, Gary ^a,c   Pedain, Christoph ^d   Wembacher Schröder, Eva ^d   Westphal, Manfred ^e,be   Kunwar, Sandeep ^f   Vogelbaum, Michael A ^g   Coan, April ^b,c   Herndon II, James E ^b,c   Raghavan, Raghu ^h   Brady, Martin L ^h   Reardon, Davi D A ^a   Friedman, Allan H ^a,c   Friedman, Henry S ^a,c   Rodríguez Ponce, M Inmaculada ^d   Chang, Susan M ^f   Mittermeyer, Stephan ^d   Croteau, Davi ⁱ   Puri, Raj K ^j   Markert, James MacDowell ^k   Prados, Michael ^f   Chen, Thomas ^l   Mamelak, Adam ^m   Cloughesy, Timothy ⁿ   Yu, John ^o   Lillehei, Kevin ^p   Piepmeier, Joseph ^q   Pan, Edward ^r   Vrionis, Frank ^s   Moffitt, H Lee ^s   Olson, Jeffrey ^t   Chandler, James ^u   Paleologos, Nina ^v   Byrne, Richard W ^w   Lesniak, Maciej ^x   Weingart, Jon D ^y   Black, Peter ^z   Mikkelsen, Tom ^aa   Uhm, Joon ^ab   Bucholz, Richard ^ac   Abrey, Lauren ^ad   Schwartz, Theodore H ^ae   Bruce, Jeffrey ^af   Asher, Anthony ^ag   Tatter, Stephen ^ai   Barnett, Gene ^g   Chiocca, Antonio E ^aj   Delashaw Jr , Johnny B ^ak   Judy, Kevin ^al   Patel, Sunil ^am   Frankel, Bruce ^an   Lang, Fred ^ao   New, Pamela ^ap   Fink, Karen ^aq   Jensen, Randy L ^ar   Shaffrey, Mark ^as   Taylor, Lynne ^at   Boling, Warren ^au   Badie, Behnam ^av   Guha, Abhijit ^aw   Mehta, Vivek ^ax   Hamilton, Mark ^ay   Eisenstat, David D ^az   Pirouzmand, Farhad ^ba   Macdonald, David ^bb   Del Maestro, Rolando ^bc   Fourney, Daryl ^bd   Mehdorn, Maximilian ^bf   Goldbrunner, Roland ^bg   Schackert, Gabriele ^bh   Unterberg, Andreas ^bi   Ram, Zvi ^bj   Cohen, Zvi ^bk   Rappaport, Zvi ^bl   Mooij, Jan Jacob ^bm   Wolbers, John G ^bn   Warnke, Peter ^bo   Papanastassiou, Varnavas ^bp   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d BRAINLAB AG   (Germany)

^e Asklepios Klinik Hamburg Altona Abteilung für Neurochirurgie   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Therataxis LLC   (United States)

ⁱ NeoPharm Inc   (United States)

^j CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o CEDARS SINAI MEDICAL CENTER   (United States)

^p UNIVERSITY OF COLORADO HOSPITAL   (United States)

^q YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r FLORIDA HOSPITAL   (United States)

^s Research Institute   (United States)

^t EMORY UNIVERSITY   (United States)

^u NORTHWESTERN UNIVERSITY   (United States)

^v EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^w RUSH MEDICAL COLLEGE   (United States)

^x UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^y JOHNS HOPKINS UNIVERSITY   (United States)

^z DANA FARBER CANCER INSTITUTE   (United States)

^aa HENRY FORD HEALTH SYSTEM   (United States)

^ab MAYO CLINIC   (United States)

^ac SAINT LOUIS UNIVERSITY   (United States)

^ad MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ae WEILL CORNELL MEDICAL COLLEGE   (United States)

^af Department of Medicine   (United States)

^ag CAROLINA NEUROSURGERY AND SPINE ASSOCIATES   (United States)

^ah DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ai WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^aj THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^ak OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^al HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^am MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^an BAPTIST MEMORIAL HOSPITAL   (United States)

^ao UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ap BAYLOR COLLEGE OF MEDICINE   (United States)

^aq UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^ar UNIVERSITY OF UTAH   (United States)

^as UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^at BENAROYA RESEARCH INSTITUTE   (United States)

^au WEST VIRGINIA UNIVERSITY   (United States)

^av University of Wisconsin Health   (United States)

^aw TORONTO WESTERN HOSPITAL   (Canada)

^ax UNIVERSITY OF ALBERTA   (Canada)

^ay CALGARY HEALTH REGION   (Canada)

^az CANCERCARE MANITOBA   (Canada)

^ba SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^bb LONDON REGIONAL CANCER PROGRAM   (Canada)

^bc MCGILL UNIVERSITY   (Canada)

^bd ROYAL UNIVERSITY HOSPITAL   (Canada)

^be UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^bf UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^bg LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^bh DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^bi UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^bj TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^bk SHEBA MEDICAL CENTER   (Israel)

^bl RABIN MEDICAL CENTER   (Israel)

^bm UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^bn ERASMUS MEDICAL CENTER   (Netherlands)

^bo WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^bp Institute of Neuro Logical Sciences   (United Kingdom)

more..

Author keywords

Brain neoplasm; Convection enhanced delivery; Drug delivery system; Interleukin 13; Planning software

Indexed keywords

ALGORITHM; ARTICLE; CANCER SURGERY; CATHETERIZATION; CENTRAL NERVOUS SYSTEM; COMPUTER PROGRAM; CONVECTION ENHANCED DELIVERY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; HAZARD RATIO; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSITION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOM SAMPLE; RETROSPECTIVE STUDY; STEREOTACTIC PROCEDURE; TUMOR LOCALIZATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CATHETERIZATION; CLINICAL TRIALS, PHASE III AS TOPIC; CONVECTION; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-13; KAPLAN-MEIER ESTIMATE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SOFTWARE; TISSUE DISTRIBUTION; TREATMENT FAILURE;

EID: 77955608850     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.11.JNS091052     Document Type: Article

References (20)

1. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076-2080, 1994
2. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595, 2003
3. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911, 1980
4. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK, Jarboe JS, et al: Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67:7983-7986, 2007
5. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, et al: Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103:923-929, 2005
6. Kunwar S: Convection enhanced delivery of IL13PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105-111, 2003
7. Kunwar S, Pai LH, Pastan I: Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 79:569-576, 1993
8. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, et al: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837-844, 2007
9. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362-1368, 1997
10. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS: Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11:703-704, 2005
11. Murad GJ, Walbridge S, Morrison PF, Garmestani K, Degen JW, Brechbiel MW, et al: Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res 12:3145-3151, 2006
12. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS: Intraputamenal infusion of glial cell line-derived neu rotrophic factor in PD: a two-year outcome study. Ann Neurol 57:298-302, 2005
13. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243-1253, 2005
14. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157-2165, 2000
15. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27-35, 2003
16. Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, et al: Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60 (2 Suppl 1):ONS89-ONS99, 2007
17. Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE II, Croteau D, et al: Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9:343-353, 2007
18. Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, et al: Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol 188:703-709, 2007
19. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, et al: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125-137, 2003
20. Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, et al: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88:93-103, 2003